Prices are checked against each store and labelled with when.
It checks today's price at every store, compares the alternatives and answers in about a minute.
Tirzepatide is the active ingredient in Mounjaro, a once-weekly injectable approved for type 2 diabetes and used off-label for chronic weight management. It works on two gut hormone receptors (GIP and GLP-1) to boost insulin release, slow stomach emptying and curb appetite. This 10 mg plan is a step-up dose: patients must have completed a 7.5 mg course first. It suits people already established on tirzepatide who are moving up under a prescriber's care, not first-time users.
In stock
This is a one-month supply of tirzepatide combined with vitamin B12, given as a once-weekly injection. Tirzepatide is given under the skin for A1C reduction and glycemic control in type 2 diabetes, and for chronic weight management. The B12 is included for energy, metabolism and sleep cycle regulation.
This 10 mg dose is only for patients who have already been prescribed 7.5 mg. Doses change depending on the month and on how well the patient tolerates the treatment. Results vary by individual. Possible benefits include enhanced insulin secretion, improved insulin sensitivity, reduced appetite and a longer feeling of fullness after eating due to delayed gastric emptying. Tirzepatide is FDA approved for the management of type 2 diabetes, and any other use is considered off-label.
The injection is self-administered in the fatty abdominal area, the back of the arm or the thigh. Take it once a week on the same day each week, at any time of day, with or without food. The most common side effects are nausea, vomiting, diarrhea and constipation. The treatment is meant to be used alongside a healthy diet and exercise, including portion control.
